Literature DB >> 7678311

Analysis of the cross-reactive anti-gp120 antibody population in human immunodeficiency virus-infected asymptomatic individuals.

K Hariharan1, P L Nara, V M Caralli, F L Norton, N Haigwood, C Y Kang.   

Abstract

This study was undertaken to analyze the specificity and neutralizing properties of cross-reactive anti-gp120 antibodies (Abs) in the sera of two human immunodeficiency virus (HIV)-infected asymptomatic individuals. Two panels of murine monoclonal anti-idiotype Abs (anti-id MAbs) were established against cross-reactive polyclonal anti-gp120 Abs purified from HIV+ sera by sequential affinity chromatography using gp120SF2- and gp120IIIB-Sepharose columns. These panels of anti-id MAbs were then used to affinity purify idiotype-positive (Id+) anti-gp120 Abs from HIV+ sera. The recovery of each of these Id+ Abs by purification indicated that several idiotypically distinct cross-reactive anti-gp120 Abs are present in sera over a wide range of concentrations. Immunological and biological studies showed that although all of the Id+ Abs were reactive against gp120SF2 and gp120IIIB, they exhibited unique epitope specificities and distinct neutralizing activities. Most of the Id+ Abs were directed against epitopes in the CD4 attachment site (CD4 site epitopes) of gp120 and exhibited a spectrum of broadly neutralizing activities. On the other hand, a minor population of Id+ Abs showed specificity for the V3 region of gp120 and exhibited limited cross-neutralizing activities. Together, these studies indicate that the CD4 site epitope-specific Abs are heterogeneous with respect to their clonality, neutralizing activity, and concentration in sera. This heterogeneity suggests that anti-gp120 Abs to the CD4 attachment site are developed in response to multiple overlapping epitopes present on the original virus isolate and/or epitopes on mutated variants which emerged over time.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7678311      PMCID: PMC237449     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  [A new allotype form of rabbit serum gamma-globulins, apparently associated with antibody function and specificity].

Authors:  J OUDIN; M MICHEL
Journal:  C R Hebd Seances Acad Sci       Date:  1963-07-17

2.  A human monoclonal antibody against the CD4-binding site of HIV1 gp120 exhibits potent, broadly neutralizing activity.

Authors:  S A Tilley; W J Honnen; M E Racho; M Hilgartner; A Pinter
Journal:  Res Virol       Date:  1991 Jul-Aug

3.  Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1.

Authors:  M Kowalski; J Potz; L Basiripour; T Dorfman; W C Goh; E Terwilliger; A Dayton; C Rosen; W Haseltine; J Sodroski
Journal:  Science       Date:  1987-09-11       Impact factor: 47.728

4.  A predominant group-specific neutralizing epitope of human immunodeficiency virus type 1 maps to residues 342 to 511 of the envelope glycoprotein gp120.

Authors:  I Berkower; D Murphy; C C Smith; G E Smith
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

5.  Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody.

Authors:  M Thali; U Olshevsky; C Furman; D Gabuzda; M Posner; J Sodroski
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

6.  Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody.

Authors:  D D Ho; J A McKeating; X L Li; T Moudgil; E S Daar; N C Sun; J E Robinson
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

7.  Use of monoclonal antibodies to identify shared idiotypes on human antibodies to native DNA from patients with systemic lupus erythematosus.

Authors:  G Solomon; J Schiffenbauer; H D Keiser; B Diamond
Journal:  Proc Natl Acad Sci U S A       Date:  1983-02       Impact factor: 11.205

8.  Effects on CD4 binding of anti-peptide sera to the fourth and fifth conserved domains of HIV-1 gp120.

Authors:  B Ardman; M Kowalski; J Bristol; W Haseltine; J Sodroski
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

9.  Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein.

Authors:  M A Skinner; R Ting; A J Langlois; K J Weinhold; H K Lyerly; K Javaherian; T J Matthews
Journal:  AIDS Res Hum Retroviruses       Date:  1988-06       Impact factor: 2.205

10.  Extensive variation of human immunodeficiency virus type-1 in vivo.

Authors:  M S Saag; B H Hahn; J Gibbons; Y Li; E S Parks; W P Parks; G M Shaw
Journal:  Nature       Date:  1988-08-04       Impact factor: 49.962

View more
  7 in total

1.  Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus.

Authors:  Indresh K Srivastava; Leonidas Stamatatos; Harold Legg; Elaine Kan; Anne Fong; Stephen R Coates; Louisa Leung; Mark Wininger; John J Donnelly; Jeffrey B Ulmer; Susan W Barnett
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

2.  A naturally occurring single basic amino acid substitution in the V3 region of the human immunodeficiency virus type 1 env protein alters the cellular host range and antigenic structure of the virus.

Authors:  T Shioda; S Oka; S Ida; K Nokihara; H Toriyoshi; S Mori; Y Takebe; S Kimura; K Shimada; Y Nagai
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

3.  Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies.

Authors:  C C Broder; P L Earl; D Long; S T Abedon; B Moss; R W Doms
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-22       Impact factor: 11.205

4.  Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities.

Authors:  P L Earl; C C Broder; D Long; S A Lee; J Peterson; S Chakrabarti; R W Doms; B Moss
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

5.  Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.

Authors:  P Roben; J P Moore; M Thali; J Sodroski; C F Barbas; D R Burton
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

6.  Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120.

Authors:  C Y Kang; K Hariharan; P L Nara; J Sodroski; J P Moore
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

7.  Anti-HIV-1 response elicited in rabbits by anti-idiotype monoclonal antibodies mimicking the CD4-binding site.

Authors:  Roberto Burioni; Nicasio Mancini; Donata De Marco; Nicola Clementi; Mario Perotti; Giovanni Nitti; Monica Sassi; Filippo Canducci; Krisha Shvela; Patrizia Bagnarelli; John R Mascola; Massimo Clementi
Journal:  PLoS One       Date:  2008-10-16       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.